Key result
Indomethacin at /kg daily is linked to higher ductus response rates than graduated dosing.
Why the study?
The therapeutic plasma indomethacin levels for effective ductus closure and associated renal side effects in premature infants with patent ductus arteriosus were not well defined.
Does a higher dose indomethacin regimen improve ductus closure compared to a lower dose regimen in premature infants with patent ductus arteriosus?
Observational
Does a higher dose indomethacin regimen improve ductus closure compared to a lower dose regimen in premature infants with patent ductus arteriosus?
Higher doses of indomethacin optimize ductus closure in premature infants with PDA without significantly increasing the severity of transient renal adverse effects.
Answers are grounded in this paper and cite their sources.
Higher indomethacin dosing may enhance PDA closure; leaves open optimal regimen and renal safety in preterm infants.
To determine the therapeutic range of plasma indomethacin levels for ductus closure, we evaluated the ductus response and renal side effects on two therapeutic regimens using different dosage; regimen I received 0.3 mg/kg q 24 h for a maximum of 3 doses, and regimen II received 0.1, 0.2 and 0.3 mg/kg at 24-hour intervals, for a maximum of 3 doses if needed. Infants in regimen I had significantly higher plasma indomethacin and higher ductus response rate than infants in regimen II. Urine output (U/O) was comparable between the regimens, but serum sodium was lower in regimen I than in regimen II. In both regimens, U/O and serum sodium return to normal by 72 h. The plasma indomethacin levels at 12 h after 1 dose correlated significantly with ductus response and hyponatremia. There appeared to be a minimal level of plasma indomethacin above which U/O decreased; with a plasma level greater than 170 ng/ml the majority (greater than 97%) of infants showed a decrease in U/O. While there was a 50% or greater chance that ductus would close when the plasma levels reached 600 ng/ml or more, a great proportion of infants would also develop renal side effects. Thus, a safe therapeutic range of plasma indomethacin appeared to be very narrow. However, when the dose of indomethacin is increased to optimize constrictive response, there is no significant increase in incidence and severity of renal adverse effects. In view of the transient nature of renal side effects, they should not hinder indomethacin therapy if ductus closure is indicated.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2019) conducted an observational in Patent Ductus Arteriosus. Indomethacin Regimen I vs. Indomethacin Regimen II (0.1, 0.2 and 0.3 mg/kg at 24-hour intervals) was evaluated on Ductus response and renal side effects. Indomethacin at /kg daily yielded higher plasma levels and ductus response rates than a graduated dosing regimen, with a ≥50% closure chance at plasma levels ≥600 ng/ml.
Synapse has enriched 10 related papers. Consider them for comparative context: